These include monoclonal antibodies (for example, bevacizumab) or small molecules (for example, anti-VEGFR tyrosine kinase inhibitors).[8] After early-phase trials established optimal dosing and safety profiles and received approval for the treatment of advanced renal cell carcinoma, pazopanib was studied in STS. Here, KDR is linked to hereditary clear cell renal cell carcinoma.